Hot Features
プレミアム
Alumis Inc (ALMS)
NASDAQ
登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
Alumis' mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor th... Alumis' mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis, and is currently being evaluated in additional Phase 2 clinical trials in patients with systemic lupus erythematosus (SLE) and non-infectious uveitis, for which we expect to report results in 2026 and by the end of 2024, respectively. 詳細を表示
– A-005 was well tolerated and demonstrated ability to cross blood-brain barrier – – Maximal TYK2 inhibition achieved with favorable pharmacokinetic profile in CNS and periphery – – Data support...
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to...
– Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition – – Continued to advance three clinical...
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to...
28-week data show ESK-001 was generally well tolerated and most patients treated with the top dose of 40 mg twice daily achieved PASI 75Three additional data presentations further support...
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to...
– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis – – Initiated Phase 1 clinical trial for A-005 in healthy participants – – Completed...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.27 | -15.3567110036 | 8.27 | 9.07 | 6.98 | 88903 | 8.30780632 | CS |
| 4 | -1.57 | -18.3197199533 | 8.57 | 9.2 | 6.98 | 123523 | 8.3613381 | CS |
| 12 | -4.01 | -36.421435059 | 11.01 | 13.11 | 6.98 | 113806 | 9.34732348 | CS |
| 26 | -4.99 | -41.6180150125 | 11.99 | 13.5 | 6.98 | 142608 | 10.95112022 | CS |
| 52 | -6.5 | -48.1481481481 | 13.5 | 13.5 | 6.98 | 152913 | 11.13803328 | CS |
| 156 | -6.5 | -48.1481481481 | 13.5 | 13.5 | 6.98 | 152913 | 11.13803328 | CS |
| 260 | -6.5 | -48.1481481481 | 13.5 | 13.5 | 6.98 | 152913 | 11.13803328 | CS |
devil dog 96
4分前
3331
5分前
GrantHorvat1
6分前
hap0206
7分前
Riley4
9分前
SSKILLZ1
9分前
chen1992
9分前
starboy
10分前
SSKILLZ1
11分前
michael702/
12分前
BTuna
12分前
SSKILLZ1
12分前
benyam
15分前
manibiotech
15分前
SSKILLZ1
15分前
StayHumble
18分前
dinogreeves
20分前
Moonboy1
20分前
Mr. C
21分前
pos_stock_hoarder
22分前
Slojab
23分前
pos_stock_hoarder
24分前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
